Post-ablative thyroglobulin level as a predictor of favourable prognosis in patients with differentiated thyroid cancer

Gadawska-Juszczyk, Klaudia; Kowalska, Aldona; Pałyga, Iwona; Mężyk, Ryszard; Słuszniak, Anna

doi:10.1530/endoabs.35.p1143

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DTC's have low lethality rates and slow indolent growth. Although 10 year survival rates are around 80%-95%, some cases have more aggressive behaviour and recurrence levels up to 35% indicating a cautious approach and long-term clinical follow-up ( 4 – 8 ). For a long time the standard treatment for these tumours was total thyroidectomy (TT) followed by iodine-131 ( 131 I) therapy and thyrotropin (TSH) suppression with levothyroxine ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Thyroglobulin/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study

Marchi

Macedo

Soares

et al. 2021

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: Thyrotropin-stimulated thyroglobulin (STg) after total thyroidectomy is a prognosis marker for differentiated thyroid carcinoma (DTC). As Tg level is influenced by thyrotropin (TSH), perhaps the STg/TSH ratio is also a prognosis marker for these tumours. We aimed to compare STg/TSH ratio and first STg level in differentiated thyroid carcinoma patients for their ability to predict the longterm response to initial treatment. Subjects and methods: This retrospective study evaluated data from 181 DTC patients for first (1 st ) STg and STg/TSH ratio, at 1-3 months post-total thyroidectomy and before iodine-131 therapy, according to response to initial therapy [Excellent/Indeterminate or Incomplete (Biochemical/Structural)] observed at final evaluation, and with the survival time with excellent/indeterminate response. Results: Cases with incomplete response presented higher STg level [225.13 ± 585.26 ng/mL versus (vs) 20.4 ± 192.9 ng/mL; p < 0.001] and STg/TSH ratio (3.01 ± 7.8 vs 0.27 ± 2.58; p < 0.001). Cutoffs of 5 ng/mL for STg and 0.085 for STg/TSH displayed sensitivities of 76.7% and 76.9%, and specificities of 79.2% and 82.6%, respectively, in predicting response to therapy. Values below these cutoffs were associated with longer survival time in excellent/indeterminate response (140.4 vs 15.9 and 144.6 vs 15.9 months, respectively). Conclusion: STg/TSH ratio has a similar performance to the 1 st STg in predicting long-term response to initial therapy.

show abstract

Section: Introductionmentioning

confidence: 99%